IDiyas

For the Inventor, By the Inventor

Maplewood, NJ, United States of America

Neil I Goldstein

USPTO Granted Patents = 13 

Average Co-Inventor Count = 2.6

ph-index = 11

Forward Citations = 361(Granted Patents)


Location History:

  • West Orange, NJ (US) (1996)
  • Maplewood, NJ (US) (1998 - 2007)

Company Filing History:

goldMedal9 out of 22 
 
Imclone Systems, Inc.
 patents
silverMedal2 out of 3 
 
Antyra Inc.
 patents
bronzeMedal1 out of 1,777 
 
Novo Nordisk A/s
 patents
4. 1 out of 247 
 
Corixa Corporation
 patents
5. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1996-2007

Loading Chart...
13 patents (USPTO):Explore Patents
1. 7173005 - Insulin and IGF-1 receptor agonists and antagonists (2007-02-06),
2. 7060808 - Humanized anti-EGF receptor monoclonal antibody (2006-06-13),
3. 7056679 - Target specific screening and its use for identifying target binders (2006-06-06),
4. 6875741 - Insulin and IGF-1 receptor agonists and antagonists (2005-04-05),
5. 6811779 - Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy (2004-11-02),
6. 6448077 - Chimeric and humanized monoclonal antibodies specific to VEGF receptors (2002-09-10),
7. 6413717 - Methods for indentifying anti-cancer agents (2002-07-02),
8. 6365157 - Monoclonal antibodies specific to VEGF receptors and uses thereof (2002-04-02),
9. 5955311 - Monoclonal antibodies specific to VEGF receptors and uses thereof (1999-09-21),
10. 5874542 - Single chain antibodies specific to VEGF receptors (1999-02-23),
11. 5861499 - Nucleic acid molecules encoding the variable or hypervariable region of (1999-01-19),
12. 5840301 - Methods of use of chimerized, humanized, and single chain antibodies (1998-11-24),
13. 5547670 - Recombinant hybrid porin epitopes (1996-08-20),

Title: Neil I Goldstein: Innovator in Biopharmaceuticals

Introduction

Neil I Goldstein is a prominent inventor based in Maplewood, NJ (US), known for his significant contributions to the field of biopharmaceuticals. With a total of 13 patents to his name, Goldstein has made remarkable advancements in therapeutic development, particularly in the areas of insulin and EGF receptor monoclonal antibodies.

Latest Patents

Goldstein's latest patents include innovative peptide sequences capable of binding to insulin and insulin-like growth factor receptors. These peptides exhibit either agonist or antagonist activity, identified from various peptide libraries. His invention highlights at least two distinct binding sites on these receptors, which selectively bind the peptides. As agonists, these peptides may serve as therapeutics to supplement or replace endogenous peptide hormones. Additionally, the antagonist peptides have potential therapeutic applications. Another notable patent involves a nucleic acid encoding a humanized antibody that binds to the human EGF receptor, with monoclonal antibody 225 serving as the complementary determining region (CDR) donor.

Career Highlights

Throughout his career, Goldstein has worked with notable companies such as Imclone Systems, Inc. and Antyra Inc. His work has significantly impacted the development of new therapeutic options in the biopharmaceutical industry.

Collaborations

Goldstein has collaborated with esteemed colleagues, including Patricia Rockwell and Renuka Pillutla, contributing to the advancement of innovative biopharmaceutical solutions.

Conclusion

Neil I Goldstein's contributions to the field of biopharmaceuticals through his patents and collaborations underscore his role as a leading inventor. His work continues to pave the way for new therapeutic developments that may enhance patient care and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…